Drug
AC 7700 clinical trials
- studies test it
- 11
- open now
- 0
- in phase 3
- 1
- first study started
- 2006
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2010 (4)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 4 |
| 2011 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 2
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Often tested with
Tested in the same studies.
Cisplatin (2) · Docetaxel (2) · Paclitaxel (1) · Carboplatin (1) · Bevacizumab (1)
Studies
Open first, then newest update. How each study uses AC 7700 is read from its arms, and is right about nine times in ten.
Testing it · 11
- Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung CancerCompletedPhase 2SanofiNCT01263886Written as ombrabulin (AVE8062)
- A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide ChemotherapiesCompletedPhase 3SanofiNCT00699517Written as OMBRABULIN (AVE8062)
- Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/PaclitaxelCompletedPhase 2SanofiNCT01332656Written as Ombrabulin (AVE8062)
- A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid TumorsCompletedPhase 1SanofiNCT01293630Written as Ombrabulin (AVE8062)
- Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid TumorsCompletedPhase 1SanofiNCT01193595Written as Ombrabulin (AVE8062)
- Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid TumorsCompletedPhase 1SanofiNCT00968916Written as ombrabulin (AVE8062)
- Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid TumorsCompletedPhase 1SanofiNCT01095302Written as OMBRABULIN (AVE8062)
- Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid TumorsCompletedPhase 1SanofiNCT01907685Written as AVE8062
- AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid TumorCompletedPhase 1SanofiNCT00719524Written as OMBRABULIN (AVE8062)
- A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid TumorCompletedPhase 1SanofiNCT01063946Written as Ombrabulin (AVE8062)
- Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid TumorsCompletedPhase 1SanofiNCT01021150Written as ombrabulin (AVE8062)
Codes
What other systems call AC 7700 · ClinicalTrials.gg INT004189
- MeSH (NLM) C400245AC 7700One source NLM
- UNII (FDA) KXZ9NDO6H0OMBRABULIN HYDROCHLORIDEConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C400245 | AC 7700 | One source NLM |
| UNII (FDA) | KXZ9NDO6H0 | OMBRABULIN HYDROCHLORIDE | Confirmed FDA, NLM |
Also registered as ombrabulin (UNII 82JB1524Q6).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.